Serveis bioanalítics i CMC per a petites molècules, productes biològics i
teràpies avançades per a la indústria de les ciències de la vida
El grup Kymos és una CRO analítica amb tres laboratoris europeus dedicats a oferir serveis bioanalítics i CMC per a la indústria de les ciències de la vida durant tot el cicle de vida del producte: des de la recerca i desenvolupament fins a la fabricació i comercialització. Estem certificats per GLP i GMP, hem estat inspeccionats amb èxit per l’EMA i la FDA i som experts en treballs analítics i de control de qualitat amb petites molècules, productes biològics i oligonucleòtids. Kymos ofereix serveis a clients de tot el món en les indústries farmacèutica, biotecnològica, veterinària, química, cosmètica i nutracèutica.
Testimonials
“We are currently developing multiple new biosimilar projects and consider Kymos one of the best CROs in Europe for drug release and testing.”
“We were positively impressed when Kymos reacted to our needs by investing in their stability capabilities, and now, two years down the line, with projects in full-swing, I can safely say that we made the right choice. In Kymos we have found a reliable, committed, trustworthy and professional partner.”
“Back in 2017 there weren’t many analytical CROs able to carry out Franz cell assays and Kymos’ pioneering work was pivotal for the registration of our product.”
“Kymos offered superior historical expertise by being exposed to so many different clients, pharmacological compounds, and therapeutic areas. They addressed and anticipated very diverse problems.”
“I have had a long and fruitful experience with Kymos and have a huge interest in their participation owing to their reliability.”
“Prolytic is our analytical partner throughout the entire drug development process. Such a long and complex process requires a laboratory you can trust. Professional yet flexible, Prolytic accompanies us through the preclinical and clinical phases.”
“Establishing robust miRNA methods for valuable results is tricky. The team at Prolytic have been a key collaboration partner. With their 30 years of experience in bioanalytics and broad know-how in different techniques, study types, and substance groups, we were able to quickly develop a reproducible and reliable analysis method for miRNAs.”
Últimes notícies
Subscriu-te aquí per estar al dia de les últimes novetats normatives, tecnològiques i d’innovació.
KOREA PHARM & BIO: Goyang, KR | 23-26 abril 2024
BIO KOREA 2024: Seül, KR | 08-10 de maig de 2024
BIO International Convention: San Diego, US | 3-6 juny 2024
Congrès POLEPHARMA Biotesting: Évreux, FR | 5-6 juny 2024
AFI Symposium: Rimini, IT | 5-7 juny 2024
BIOPLUS – INTERPHEX KOREA: Seül, KR | 10-12 de juliol de 2024
Farmaforum: Madrid, ES | 25-26 setembre 2024
Biomarkers Europe 2024: Basilea, CH | 30 de setembre – 01 d’octubre de 2024
CPHI 2024: Milan, IT | 8-10 octubre 2024
BIO-Europe Autumn: Estocolm, SE | 4-6 novembre 2024
European Bioanalysis Forum: Barcelona, ES | 20-22 de novembre de 2024
TIDES Europe: Hamburg, DE | 12-14 novembre 2024
PharmaLab Congress: Düsseldorf, DE | 25-27 novembre 2024
I4ID 2024: Lyon, FR | 27-28 novembre 2024
